Cresco Labs Inc.

CL

CA22587M1068

Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 14:32:36 2024-05-16 EDT			5-day change	1st Jan Change
3.14 ^CAD	+11.74%		+14.00%	+75.14%

05-15	Transcript : Cresco Labs Inc., Q1 2024 Earnings Call, May 15, 2024
05-15	Earnings Flash (CL) CRESCO LABS Posts Q1 Revenue $184.3M	MT

Cresco Labs Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023

August 16, 2023 at 07:30 am

Cresco Labs Inc. reported earnings results for the second quarter ended June 30, 2023. For the second quarter, the company reported sales was USD 197.89 million compared to USD 218.23 million a year ago. Net loss was USD 43.46 million compared to USD 8.3 million a year ago.

Latest news about Cresco Labs Inc.

Transcript : Cresco Labs Inc., Q1 2024 Earnings Call, May 15, 2024	05-15
Earnings Flash (CL) CRESCO LABS Posts Q1 Revenue $184.3M	05-15	MT
Jushi Holdings Inc. Brief: Appointed Todd West as Chief Operating Officer, Effective April 12, 2024; Most Recent Role Was As Executive Vice President of Operations at Cresco Labs Inc	04-15	MT
Cresco Labs Swings to Profit in Q4, Revenue Drops; Up 10.4%	03-13	MT
Cresco Labs Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-13	CI
Cresco Labs Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Cresco Labs Inc. Provides Revenue Guidance for the First Quarter of 2024	03-13	CI
Transcript : Cresco Labs Inc., Q4 2023 Earnings Call, Mar 13, 2024	03-13
Cresco Labs Swings to Profit in Q4, Revenue Drops	03-13	MT
Cresco Labs Brief: Fourth quarter revenue of US$188 million; net income of $5 million.	03-13	MT
Cresco Labs Continues Retail Expansion in Pennsylvania with New Gettysburg Store	02-23	CI
Cresco Labs Inc. Promotes Greg Butler to the Position of President	02-01	CI
Cresco Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Transcript : Cresco Labs Inc., Q3 2023 Earnings Call, Nov 15, 2023	11-15
Earnings Flash (CL) CRESCO LABS Posts Q3 Revenue $190.6M	11-15	MT
Cresco Labs Unlocking US$32 Million in Non-Dilutive Capital	23-10-19	MT
The Mint Cannabis completed the acquisition of Encanto Green Cross Dispensary, LLC from Cresco Labs Inc. (CNSX:CL) for $6.5 million.	23-10-18	CI
Cresco Labs Inc. Launches Good News Brand in Pennsylvania with New Sweet Troches	23-10-09	CI
Cresco Labs Inc. Expands Sunnyside in Central Pennsylvania with New Store in Altoona	23-10-05	CI
SAFER Banking Act Passes Banking Committee, Sent to the Floor, Notes Wedbush	23-09-27	MT
Cresco Labs Launches New Brands in Florida; Down 6.2%	23-09-21	MT
Cresco Labs Launches New Brands in Florida	23-09-21	MT
Cresco Labs Expands Florida Brand Portfolio with Launch of Floracal and Cresco Live Rosin and Flower Products	23-09-21	CI
Piper Sandler on US Opportunities For Cannabis Companies	23-09-18	MT
Cresco Labs Inc. Opens 33Rd Florida Sunnyside in Jacksonville, 70Th Store Nationwide	23-09-12	CI

Chart Cresco Labs Inc.

Duration

Period

More charts

Company Profile

Cresco Labs Inc. is an integrated multi-state cannabis operator in the United States. The Company is licensed to cultivate, manufacture, and sell retail and medical cannabis products primarily through Sunnyside, Cresco Labsâ national dispensary brand, and third-party retail stores. Its family brands include Cresco, High Supply, Good News, Wonder Wellness Co., FloraCal Farms, Remedi and Mindyâs. Its portfolio consists of over 400 products. The Company's products are sold in over 1,600 dispensaries across the country. Its Cresco offers consistent strains, available in a variety of product forms at dispensaries and retail locations nationwide. Its High Supply lab-tested; and available in vape carts, vape pens, flower, popcorn, shake, shorties and concentrates. Its Remedi products provide a consistent and trusted alternative to traditional pharmaceuticals like opioids. Its Mindyâs offers dosed edibles created by James Beard. It is the wholesaler of branded cannabis products.

Sector

Pharmaceuticals

Calendar

2024-06-09 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Cresco Labs Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.066 USD

Average target price

4.41 USD

Spread / Average Target

+113.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CRESCO LABS INC.	+75.14%	722M
ELI LILLY AND COMPANY	+32.89%	709B
NOVO NORDISK A/S	+30.77%	595B
JOHNSON & JOHNSON	-1.86%	367B
MERCK & CO., INC.	+20.18%	334B
ABBVIE INC.	+5.85%	289B
ASTRAZENECA PLC	+14.77%	239B
NOVARTIS AG	+9.13%	211B
ROCHE HOLDING AG	-3.97%	203B
AMGEN INC.	+8.96%	171B

Other Pharmaceuticals

Cresco Labs Inc.

Equities

CL

CA22587M1068

Pharmaceuticals

Cresco Labs Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023

EPS Revisions